Like B-12, L-carnitine is not a peptide. It's a small nutrient your body makes from two amino acids (lysine and methionine) and also gets from red meat, and its main job is shuttling fat into your cells' mitochondria to be burned for energy. It's a genuinely approved drug for people who are truly carnitine-deficient. But the popular uses — fat loss, gym performance — have weak or mixed evidence, and there's a real cardiovascular question (TMAO) around high-dose supplementation.
L-carnitine/levocarnitine is a conditionally essential nutrient and the obligatory cofactor of the carnitine shuttle that transports long-chain fatty acids across the inner mitochondrial membrane for β-oxidation. Levocarnitine (Carnitor) is FDA-approved for primary systemic carnitine deficiency and for carnitine deficiency in end-stage renal disease on dialysis; the broad consumer uses (weight loss, performance, fatigue) are far less well-supported, and a gut-microbiome → TMAO pathway raises a cardiovascular caution.
L-carnitine (β-hydroxy-γ-N-trimethylaminobutyrate) is a quaternary ammonium compound; only the L-isomer is biologically active — D-carnitine competitively inhibits carnitine acyltransferases and is considered harmful. It enables CPT1/CPT2-mediated acyl-group transfer into the mitochondrial matrix, and gut bacteria metabolize it via γ-butyrobetaine to trimethylamine and then hepatic TMAO, a metabolite associated with atherosclerosis. CAS 541-15-1; C₇H₁₅NO₃; 161.2 g/mol.
L-carnitine is the atlas's second deliberate non-peptide entry, alongside B-12: a small quaternary-ammonium nutrient (made from lysine and methionine), not a peptide, often mis-filed as one by supplement vendors. Its honest picture has three parts. First, the carnitine shuttle is genuinely essential biochemistry, and levocarnitine is an FDA-approved drug for true carnitine deficiency — primary genetic deficiency and the secondary deficiency seen in dialysis patients (Grade A). Second, the consumer uses that drive most sales — fat loss, athletic performance, anti-fatigue — rest on weak or mixed evidence in people who aren't deficient. Third, there's a real cardiovascular wrinkle: gut bacteria convert L-carnitine to TMAO, a metabolite associated with atherosclerosis, which is flagged even in the FDA label for high-dose use in renal patients. The page keeps those three honestly separate.
L-carnitine's core mechanism is clean and textbook-established: it's the obligatory carrier that moves long-chain fatty acids across the inner mitochondrial membrane so they can be burned for energy. Without it, fat can't reach the furnace, which is why genuine deficiency causes muscle weakness, cardiomyopathy, and hypoglycemia. That makes the mechanism grades genuinely high (A/B) — established biochemistry, not hypothesis. The catch is what happens to excess oral carnitine: gut bacteria metabolize it through γ-butyrobetaine to trimethylamine, which the liver oxidizes to TMAO, a metabolite associated with atherosclerosis. So the same molecule that's essential for fat metabolism has a microbiome side road that's the main reason to be cautious about chronic high-dose supplementation — and it's the rare case where the "double-edged sword" is metabolic rather than mitogenic.
| Step | Protein | Action |
|---|---|---|
| 1 | CPT1 (outer membrane) | Acyl-CoA + carnitine → acylcarnitine |
| 2 | Translocase (CACT) | Acylcarnitine across inner membrane |
| 3 | CPT2 (matrix side) | Acylcarnitine → acyl-CoA + carnitine |
| 4 | β-oxidation (CPT system) | Acyl-CoA burned for ATP |
| Form | Best-studied role |
|---|---|
| L-carnitine (levocarnitine) | Deficiency replacement (approved) |
| Acetyl-L-carnitine (ALCAR) | CNS / neuropathy / cognition |
| Propionyl-L-carnitine (PLC) | Peripheral artery disease / angina |
| L-carnitine L-tartrate (LCLT) | Exercise recovery |
Like B-12, L-carnitine spans two worlds: an FDA-approved drug (levocarnitine) for genuine carnitine deficiency, and an OTC supplement taken for fat loss, performance, and fatigue. The approved side is the strongest: primary systemic deficiency and ESRD/dialysis deficiency have labeled regimens (Grade A/D). Supplement dosing is typically 1–3 g/day oral, but oral bioavailability is poor (~14–18%), so much of a large oral dose isn't absorbed — and the unabsorbed fraction is exactly what gut bacteria turn into TMAO. The working units are mg/g for oral and mg/kg for clinical IV. The calculator below handles IV concentration math (clinical reference) and oral dose-splitting; it's not a self-dosing recommendation, and deficiency treatment belongs under clinician care.
| Band | Dose | Context | Grade |
|---|---|---|---|
| Dietary baseline | ~20–200 mg/day | Omnivore diet (red meat) | A |
| Low supplement | 500 mg–1 g/day | General supplementation | D |
| Standard supplement | 1–2 g/day | Most consumer trials | B/C |
| High supplement | 2–3 g/day | Upper common range | B/C |
| Clinical deficiency | Higher, clinician-set | Primary/secondary deficiency | A/D |
| Dialysis IV | ~10–20 mg/kg post-dialysis | ESRD secondary deficiency | A/D |
| Body weight | @ 10 mg/kg | @ 20 mg/kg |
|---|---|---|
| 55 kg | 550 mg | 1100 mg |
| 70 kg | 700 mg | 1400 mg |
| 85 kg | 850 mg | 1700 mg |
| 100 kg | 1000 mg | 2000 mg |
IV dialysis dosing is weight-based and clinician-directed; oral supplement use is fixed-dose. Reference only.
| Trigger | Action | Rationale |
|---|---|---|
| GI upset (cramps, diarrhea, nausea) | Reduce dose / divide further | GI reactions result from too-rapid consumption |
| Fishy body odor | Reduce dose; consider TMAO/FMO3 context | Trimethylaminuria-type effect from TMA |
| ESRD / severe renal impairment | Clinician-directed only; avoid high oral | TMA/TMAO accumulation risk |
| Cardiovascular risk + high red-meat diet | Reassess need; don't megadose | TMAO-associated CVD signal |
| Seizure disorder | Caution; monitor | Label notes increased seizure frequency reports |
| No deficiency, using for fat loss | Set honest expectations | Weak/mixed evidence outside deficiency |
| Marker | For deficiency? | For "optimization"? |
|---|---|---|
| Plasma free & total carnitine | Yes | No |
| Acylcarnitine profile | Yes (metabolic dx) | No |
| Plasma TMAO | Research / CV-risk context | No |
| Lipid panel (LDL) | CV safety context | No |
| Renal function | Yes (dosing safety) | No |
| Type | Cause |
|---|---|
| Primary | Genetic transporter (OCTN2/SLC22A5) defect |
| Secondary | Dialysis, certain drugs, metabolic disorders |
| Aspect | Detail |
|---|---|
| Bioavailability | IV ~100% vs oral ~14–18% |
| TMAO risk | IV bypasses gut conversion |
| Property | Detail |
|---|---|
| CNS penetration | Better than L-carnitine |
| Acetyl donation | Acetylcholine / phospholipids |
| If you are… | Likely effect |
|---|---|
| Carnitine-deficient | Real benefit (corrects deficiency) |
| Not deficient | Small/inconsistent fat-loss or performance effect |
L-carnitine is dosed in milligrams/grams (oral) or mg/kg (IV in dialysis). This calculator estimates the draw volume for a clinical IV solution and the number of split oral doses; it's reference math, not a self-dosing recommendation. Deficiency treatment belongs under clinician care, and oral absorption is only ~14–18%.
"Est. absorbed" applies the ~16% oral bioavailability midpoint — a reminder that most of a large oral dose isn't absorbed (and the remainder feeds the gut-TMAO pathway).
Most L-carnitine "stacks" are fat-loss bundles (with caffeine, CLA, green tea) where carnitine's own contribution is the weak link. A few combinations have a real rationale: the carnitine forms themselves are sometimes used together for distinct targets (ALCAR for nerves, PLC for circulation), and there's an interesting interaction with choline/betaine and the TMAO pathway worth understanding rather than ignoring. The genuinely important "combination" is dietary context: in people who eat a lot of red meat, adding high-dose carnitine pushes more substrate through the gut-TMAO pathway, so the cardiovascular calculus is different than for a vegetarian who's actually low. The hard constraint: don't megadose carnitine in renal impairment, and don't treat it as a fat-loss shortcut that lets you skip the basics.
| Context | Implication |
|---|---|
| High red-meat diet | More TMAO substrate |
| High baseline TMAO | Stronger CVD association |
| Form | Target |
|---|---|
| ALCAR | Nerves / brain |
| PLC | Circulation |
| Claim | Reality |
|---|---|
| "Synergistic fat loss" | Carnitine effect weak |
| Drug | Effect |
|---|---|
| Valproate | Carnitine depletion / hyperammonemia |
At typical doses L-carnitine is well tolerated; the common issues are GI (cramps, nausea, diarrhea from too-rapid consumption) and a fishy body odor from trimethylamine. It's the rare supplement where the most serious safety question isn't acute toxicity but a chronic-exposure signal: the gut-microbiome → TMAO pathway, which has been associated with atherosclerosis and adverse cardiovascular outcomes — and which the FDA label itself flags for high-dose use in renal failure. A 2022 randomized trial even found higher LDL and greater carotid plaque stenosis in some supplement users. None of this changes the value of treating genuine deficiency (where the benefit is clear), but it's a real reason not to megadose carnitine "for energy" if you aren't deficient, especially with cardiovascular risk or a high-meat diet. The other firm caution is stereochemical: use L-carnitine, never DL.
Carnitine won't hurt you with a single dose, and treating true deficiency is clearly beneficial. The honest concern is chronic high-dose supplementation in people who aren't deficient — the TMAO pathway is a slow cardiovascular signal, not an acute toxicity, which is exactly why it's easy to ignore and worth taking seriously.
The TMAO concern is amplified by a high-red-meat diet (more substrate) and by renal impairment (less clearance, more accumulation — the FDA label's specific warning). For someone with normal kidneys treating a real deficiency, the benefit dominates; for a meat-heavy dieter megadosing "for energy," the risk-benefit is far less favorable.
Use L-carnitine, never racemic DL-carnitine, since the D-enantiomer actively blocks the shuttle. Match the form to the goal (ALCAR for nerves, PLC for circulation), and remember that "fat-burner" framing oversells what carnitine does in people who already have normal carnitine status.
| Condition / scenario | Concern | Severity |
|---|---|---|
| DL-carnitine / D-carnitine use | Competitive shuttle inhibition — functional deficiency | High |
| Severe renal impairment / ESRD (high oral) | TMA/TMAO accumulation | High |
| Established CVD + high-meat diet (megadose) | TMAO-associated risk | Moderate–High |
| Seizure disorder | Reports of increased seizure frequency | Moderate |
| Trimethylaminuria (FMO3 variants) | Fishy-odor / TMA handling | Moderate |
| Hypothyroidism | Carnitine may antagonize thyroid action (theoretical) | Moderate |
| Pregnancy / lactation | Pregnancy Category B (levocarnitine); clinician-guided | Caution |
| Anticoagulant (warfarin) use | Possible INR potentiation reports | Monitor |
| Athletic competition (IV drips) | Substance permitted; IV-method rules may apply | Caution |
| "Fat-burner" use without deficiency | Weak benefit; TMAO exposure for little gain | Caution |
L-carnitine's evidence is layered. The bedrock is the carnitine shuttle and the treatment of genuine deficiency — established biochemistry plus an FDA-approved drug (Grade A). A middle tier covers specific clinical conditions where particular forms have real but condition-specific support: propionyl-L-carnitine for intermittent claudication/PAD and angina, acetyl-L-carnitine for diabetic neuropathy and some cognitive endpoints — generally Grade B/C, with mixed trial quality. The weakest tier is the consumer headline: fat loss and athletic performance in non-deficient people, where meta-analyses show small, inconsistent, or null effects. Layered on top is the TMAO cardiovascular literature — a genuine safety signal (Grade B/P) that complicates the "more is better" supplement narrative. The page grades each tier honestly rather than letting the strong deficiency evidence halo the weak fat-loss claims.
The label defines carnitine's approved role: primary systemic carnitine deficiency and secondary deficiency in ESRD on dialysis, with the fatty-acid-energy-substrate rationale, GI-reaction note, the renal TMA/TMAO accumulation warning, non-mutagenicity, and Pregnancy Category B. The regulatory backbone of the page.
The authoritative overview: biosynthesis from lysine/methionine, the carnitine shuttle, dietary sources, conditional essentiality, the deficiency states, and a careful summary of the TMAO/cardiovascular literature including the dose-dependent CVD associations in high-TMAO individuals and the 2022 RCT. Anchors mechanism and the safety controversy.
The established biochemistry of CPT1/CACT/CPT2-mediated long-chain fatty-acid transport into the mitochondrial matrix — the textbook mechanism that makes carnitine essential and grounds the Grade-A mechanism nodes. Deficiency in any shuttle component causes characteristic metabolic disease.
The line of work showing dietary L-carnitine is metabolized by gut bacteria via γ-butyrobetaine to trimethylamine and hepatic TMAO, a proatherogenic metabolite — the mechanistic basis for the cardiovascular caution and the reason red-meat/carnitine intake links to CVD risk through the microbiome.
A 6-month randomized trial in ~157 metabolic-syndrome adults that found no difference in total plaque volume but higher total/LDL cholesterol with L-carnitine, and ~9.3% greater carotid stenosis in a subgroup — concrete clinical-trial evidence behind the cautionary framing of high-dose supplementation.
Trials of propionyl-L-carnitine (PLC) for peripheral artery disease/intermittent claudication, where the form's support of ischemic-muscle energy metabolism produced walking-distance improvements in some studies — a condition-specific, form-specific Grade-B/C use distinct from generic carnitine supplementation.
Trials and reviews of ALCAR for diabetic peripheral neuropathy and related endpoints, with mixed-to-modest pain and nerve-function improvements — a form-specific use with real but inconsistent support, kept separate from plain L-carnitine's deficiency indication.
Meta-analyses of carnitine for body weight and athletic performance generally report small, inconsistent, or null effects in non-deficient people — the evidence behind grading the "fat-burner" headline at C/D rather than letting marketing set expectations.
The identity record: L-carnitine / levocarnitine, CAS 541-15-1, C₇H₁₅NO₃, 161.2 g/mol, a quaternary ammonium amino-acid derivative — confirming it is not a peptide and that only the L-isomer is biologically active.
Carnitine itself is not on the WADA Prohibited List, but large-volume IV infusions are restricted by the method rule (>100 mL per 12 h outside allowed medical contexts) — relevant to the "IV carnitine drip" practice marketed to athletes.
Because L-carnitine isn't a peptide, the useful comparison is among its own forms, which target different systems and aren't interchangeable. Plain L-carnitine (levocarnitine) is the deficiency-replacement workhorse and the only one with broad FDA approval; acetyl-L-carnitine (ALCAR) penetrates the CNS and is studied for nerves and cognition; propionyl-L-carnitine (PLC) supports ischemic-muscle energetics and is studied for PAD/angina; and L-carnitine L-tartrate (LCLT) is the exercise-recovery form. The table keeps the approval reality honest — levocarnitine is the approved drug; the others are largely supplement-grade with condition-specific evidence — and contrasts carnitine with B-12 as the atlas's other non-peptide metabolic entry.
| Compound / form | Primary use | Mechanism class | Evidence tier | Route | Regulatory status |
|---|---|---|---|---|---|
| L-carnitine (levocarnitine) | Carnitine deficiency replacement | Carnitine-shuttle cofactor | A for deficiency; C/D fat loss | Oral, IV | FDA-approved (Carnitor) |
| Acetyl-L-carnitine (ALCAR) | Neuropathy / cognition | CNS-penetrant acetyl donor | B/C condition-specific | Oral | Supplement (varies) |
| Propionyl-L-carnitine (PLC) | PAD / angina | Ischemic-muscle energetics | B/C condition-specific | Oral / IV | Supplement / Rx (varies) |
| L-carnitine L-tartrate (LCLT) | Exercise recovery | Carnitine + tartrate salt | C mixed | Oral | Supplement |
| Vitamin B-12 (cross-ref) | B-12 deficiency | Corrinoid vitamin cofactor | A for deficiency | Oral / IM | FDA-approved |
Because L-carnitine is not a peptide, these are related compounds — metabolic cofactors and pathway partners — rather than related peptides.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. Like B-12, L-carnitine earns genuine Grade-A sources — the FDA Carnitor label, the NIH ODS fact sheet, and the established carnitine-shuttle biochemistry — because they back real approved/established facts (deficiency treatment, the mechanism). The TMAO cardiovascular literature and the 2022 supplementation RCT are Grade B (real mechanistic and trial evidence, evolving interpretation); the form-specific PAD and neuropathy uses are Grade B/C; identity and WADA records are D. There is no high-grade source supporting "L-carnitine as a fat-burner in non-deficient people," which is why that use is graded C/D throughout. The grade pattern makes the page's core point visible: strong for deficiency, real-but-specific for a few conditions, weak for the mass-market fat-loss claim, with a genuine TMAO caution.